...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Report Of Exempt Distribution.
3
Apr 16, 2024 03:39PM
2
Apr 18, 2024 12:30AM

"I'm still betting that Resverlogix will survive. My glass is still half full for RVX"

Just a reminder, the same guy that's had zero success in 20+ years @ rvx is the same guy thats been ruining zenith for 10+ years with zero success.

Share
New Message
Please login to post a reply